Literature DB >> 26892556

An antibacterial vaccination strategy based on a glycoconjugate containing the core lipopolysaccharide tetrasaccharide Hep2Kdo2.

Lingbing Kong1, Balakumar Vijayakrishnan1, Michael Kowarik2, Jin Park1, Alexandra N Zakharova1, Larissa Neiwert2, Amirreza Faridmoayer2, Benjamin G Davis1.   

Abstract

Certain non-mammalian cell wall sugars are conserved across a variety of pathogenic bacteria. This conservation of structure, combined with their structural differences when compared with mammalian sugars, make them potentially powerful epitopes for immunization. Here, we report the synthesis of a glycoconjugate that displays the so-called 'inner core' sugars of Gram-negative bacterial cell walls. We also describe an antibacterial vaccination strategy based on immunization with the glycoconjugate and the subsequent administration of an inhibitor that uncovers the corresponding epitope in pathogenic bacteria. The core tetrasaccharide, Hep2Kdo2, a common motif in bacterial lipopolysaccharides, was synthesized and attached via a chain linker to a diphtheria toxin mutant carrier protein. This glycoconjugate generated titres of antibodies towards the inner core tetrasaccharide of the lipopolysaccharide, which were capable of binding the cell-surface sugars of bacterial pathogenic strains including Neisseria meningitidis, Pseudomonas aeruginosa and Escherichia coli. Exposure of bacterial lipopolysaccharide in in vitro experiments, using an inhibitor of capsular polysaccharide transport, enabled potent bacterial killing with antiserum.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26892556     DOI: 10.1038/nchem.2432

Source DB:  PubMed          Journal:  Nat Chem        ISSN: 1755-4330            Impact factor:   24.427


  42 in total

1.  Development, characterization, and functional activity of a panel of specific monoclonal antibodies to inner core lipopolysaccharide epitopes in Neisseria meningitidis.

Authors:  Margaret Anne J Gidney; Joyce S Plested; Suzanne Lacelle; Philip A Coull; J Claire Wright; Katherine Makepeace; Jean-Robert Brisson; Andrew D Cox; E Richard Moxon; James C Richards
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 2.  Fourteen years in resistance.

Authors:  David M Livermore
Journal:  Int J Antimicrob Agents       Date:  2012-03-03       Impact factor: 5.283

3.  Analysis of the dispersity in carbohydrate loading of synthetic glycoproteins using MALDI-TOF mass spectrometry.

Authors:  Mitul K Patel; Balakumar Vijayakrishnan; Julia R Koeppe; Justin M Chalker; Katie J Doores; Benjamin G Davis
Journal:  Chem Commun (Camb)       Date:  2010-10-29       Impact factor: 6.222

4.  The structure of the lipooligosaccharide (LOS) from the alpha-1,2-N-acetyl glucosamine transferase (rfaK(NMB)) mutant strain CMK1 of Neisseria meningitidis: implications for LOS inner core assembly and LOS-based vaccines.

Authors:  M M Rahman; C M Kahler; D S Stephens; R W Carlson
Journal:  Glycobiology       Date:  2001-08       Impact factor: 4.313

5.  Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.

Authors:  Jamie Findlow; Ray Borrow; Matthew D Snape; Tom Dawson; Ann Holland; Tessa M John; Anita Evans; Karen L Telford; Ellen Ypma; Daniela Toneatto; Philipp Oster; Elizabeth Miller; Andrew J Pollard
Journal:  Clin Infect Dis       Date:  2010-10-18       Impact factor: 9.079

Review 6.  Context and complexity: the next big thing in synthetic glycobiology.

Authors:  Todd L Lowary
Journal:  Curr Opin Chem Biol       Date:  2013-12       Impact factor: 8.822

7.  Chiral-auxiliary-mediated 1,2-cis-glycosylations for the solid-supported synthesis of a biologically important branched alpha-glucan.

Authors:  Thomas J Boltje; Jin-Hwan Kim; Jin Park; Geert-Jan Boons
Journal:  Nat Chem       Date:  2010-05-23       Impact factor: 24.427

8.  Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.

Authors:  Francesca Micoli; Maria Rosaria Romano; Marta Tontini; Emilia Cappelletti; Massimiliano Gavini; Daniela Proietti; Simona Rondini; Erwin Swennen; Laura Santini; Sara Filippini; Cristiana Balocchi; Roberto Adamo; Gerd Pluschke; Gunnstein Norheim; Andrew Pollard; Allan Saul; Rino Rappuoli; Calman A MacLennan; Francesco Berti; Paolo Costantino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

9.  Chemoenzymatic synthesis of the branched oligosaccharides which correspond to the core structures of N-linked sugar chains.

Authors:  I Matsuo; M Isomura; T Miyazaki; T Sakakibara; K Ajisaka
Journal:  Carbohydr Res       Date:  1997-12       Impact factor: 2.104

Review 10.  Vaccines for the twenty-first century society.

Authors:  Rino Rappuoli; Christian W Mandl; Steven Black; Ennio De Gregorio
Journal:  Nat Rev Immunol       Date:  2011-11-04       Impact factor: 53.106

View more
  9 in total

1.  Antibacterials: A sweet vaccine.

Authors:  David Bundle
Journal:  Nat Chem       Date:  2016-03       Impact factor: 24.427

Review 2.  E. coli Group 1 Capsular Polysaccharide Exportation Nanomachinary as a Plausible Antivirulence Target in the Perspective of Emerging Antimicrobial Resistance.

Authors:  Shivangi Sachdeva; Raghuvamsi V Palur; Karpagam U Sudhakar; Thenmalarchelvi Rathinavelan
Journal:  Front Microbiol       Date:  2017-01-31       Impact factor: 5.640

3.  Synthesis of an Undecasaccharide Featuring an Oligomannosidic Heptasaccharide and a Bacterial Kdo-lipid A Backbone for Eliciting Neutralizing Antibodies to Mammalian Oligomannose on the HIV-1 Envelope Spike.

Authors:  Nino Trattnig; Markus Blaukopf; Jean-François Bruxelle; Ralph Pantophlet; Paul Kosma
Journal:  J Am Chem Soc       Date:  2019-04-30       Impact factor: 15.419

Review 4.  Bacterial biopolymers: from pathogenesis to advanced materials.

Authors:  M Fata Moradali; Bernd H A Rehm
Journal:  Nat Rev Microbiol       Date:  2020-01-28       Impact factor: 60.633

5.  Abundance of Lipopolysaccharide Heptosyltransferase I in Human Gut Microbiome and Its Association With Cardiovascular Disease and Liver Cirrhosis.

Authors:  Shujin Lin; Hui Zhang; Xueke Wang; Ting Lin; Zihan Chen; Jingfeng Liu; Jianmin Wang
Journal:  Front Microbiol       Date:  2021-11-30       Impact factor: 5.640

6.  Semisynthetic Glycoconjugate Vaccine Candidates against Escherichia coli O25B Induce Functional IgG Antibodies in Mice.

Authors:  Arun Naini; Max Peter Bartetzko; Someswara Rao Sanapala; Felix Broecker; Victoria Wirtz; Marilda P Lisboa; Sharavathi G Parameswarappa; Daniel Knopp; Jessica Przygodda; Matthias Hakelberg; Rosalind Pan; Axay Patel; Laurent Chorro; Arthur Illenberger; Christopher Ponce; Srinivas Kodali; Jacqueline Lypowy; Annaliesa S Anderson; Robert G K Donald; Arne von Bonin; Claney L Pereira
Journal:  JACS Au       Date:  2022-08-31

7.  Synthesis of a Pentasaccharide Fragment Related to the Inner Core Region of Rhizobial and Agrobacterial Lipopolysaccharides.

Authors:  Nino Trattnig; Jean-Baptiste Farcet; Philipp Gritsch; Anna Christler; Ralph Pantophlet; Paul Kosma
Journal:  J Org Chem       Date:  2017-10-26       Impact factor: 4.354

Review 8.  Potential targets for next generation antimicrobial glycoconjugate vaccines.

Authors:  Francesca Micoli; Paolo Costantino; Roberto Adamo
Journal:  FEMS Microbiol Rev       Date:  2018-05-01       Impact factor: 16.408

9.  Conjugation of Synthetic Trisaccharide of Staphylococcus aureus Type 8 Capsular Polysaccharide Elicits Antibodies Recognizing Intact Bacterium.

Authors:  Ming Zhao; Chunjun Qin; Lingxin Li; Haotian Xie; Beining Ma; Ziru Zhou; Jian Yin; Jing Hu
Journal:  Front Chem       Date:  2020-04-28       Impact factor: 5.221

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.